BUSINESS BRIEF
Established in 2019, this privately held specialty chemical company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and cosmetic ingredients. Operating from an 80,000-litre owned facility in South India, the company caters to niche B2B clients in the pharmaceutical and skincare sectors.
Key Highlights:
- 3X revenue growth in 2 years
- Top SKUs: Methyl Propanoate derivatives, Diethylhexyl Butamide Triazone, Ethyl Hexyl Triazone
- Facility Utilization: 60–70%, with strong scalability potential
- Licenses in place: API Test License, Drug License, Environmental Clearance
- Workforce: 45 permanent + contract staff
- Promoter with 27+ years of pharma industry experience
- Clean regulatory standing, compliant infrastructure
- Current liabilities: INR 14 Cr term loan + INR 6 Cr CC
Assets Overview
Tangible assets:
- Land: INR 3 crore
- Plant and machinery: INR 40 crores
Facilities Overview
Operates from an owned facility
- Total land area: 5 acres.
- Built-up area: 44,000 sq. ft.
Products & Services
- Anti-depressants
- Anti-allergy APIs
- Oncology & Pain management ingredients
- UV filters for cosmetics
Proposal
Industry
Pharmaceuticals
Sub Industry
Pharmaceutical Manufacturing (Bulk Drug & API)
Nature of Business
B2B
Sector
Manufacturing (Contract Manufacturing)
Reason for sell-off
Financial or Operational Challenges
Location
India
Region
Southern
Open For Dilution
100 % (Complete Buyout)
Top Customer
Deal Size
INR 45 - 50 Cr
Justification
Based on market multiple. Includes physical assets worth INR 43 crore
Business Operation Information
Financial Information |
2025 (in INR Cr) | 2024 (in INR Cr) | 2023 (in INR Cr) |
|---|---|---|---|
Sales |
37.5 | 19.43 | 7.1 |
EBITDA |
|||
PAT |
